Indianapolis, Indiana — Eli Lilly announced promising results for its new oral obesity medication, orforglipron, which demonstrated a potential for patients to lose nearly 12% of their body weight, equating to about 27 pounds, over a 72-week trial period. Despite this encouraging data, the company’s shares dipped more than 12% in premarket trading following the release, as investor expectations centered on even higher weight-loss outcomes.

The trial findings revealed that while the average weight loss across all participants was 11.2%, many analysts had looked for results closer to 15%. Some medical professionals noted that while the weight loss is significant, it slightly lags behind the results seen with established treatments like Novo Nordisk’s Wegovy, a weekly injection. Concerns were raised regarding the number of patients who discontinued the medication due to side effects during the study.

Nevertheless, some experts expressed optimism about orforglipron’s potential, particularly for individuals who prefer non-injection methods. Dr. Jaime Almandoz from UT Southwestern Medical Center applauded the results, emphasizing the significant outcomes achieved with an oral agent, which could reshape obesity treatment options for those hesitant to use injectables.

Dr. Mihail Zilbermint from Johns Hopkins echoed this sentiment, asserting that, despite some tolerability issues, the pill could revolutionize treatment pathways for obese patients. This research is among the most scrutinized in the pharmaceutical sector this year, succeeding earlier positive findings from a phase three trial focused on diabetes patients.

According to Ken Custer, Eli Lilly’s president for cardiometabolic health, the company intends to submit trial data for regulatory review by year’s end, with a potential market entry in 2026. He noted that, while there are approximately 8 million individuals currently using injectable obesity medications, the market could potentially serve around 170 million patients who could benefit from these therapies.

The ease of administering an oral pill could address supply chain challenges currently faced with injections, making it a more appealing option for both patients and healthcare providers. Dr. Amy Sheer from the University of Florida hopes that orforglipron will offer a more affordable alternative to existing injectable treatments, which often carry high costs due to their delivery devices. Many insurance plans still do not cover GLP-1 medications for obesity, with prices often exceeding $1,000.

Trial results also highlighted that more than 59% of participants lost at least 10% of their body weight, with a notable 39% shedding a minimum of 15%. However, analysts pointed out that the treatment’s tolerability varied, with 10.3% of participants on the highest dose opting to discontinue due to side effects, primarily gastrointestinal issues.

While some health practitioners raised concerns about the higher discontinuation rates, Dr. Sheer suggested that the availability of an oral option might encourage physicians to prescribe GLP-1s more confidently, especially for patients wary of injections. The overall decision to prescribe orforglipron will likely depend on individual patient preferences and specific medical considerations.

Detailed findings from the trial are set to be presented at a European medical conference in September and published in a peer-reviewed journal later. As interest in GLP-1 medications grows, Eli Lilly is strategically positioned ahead of competitors in developing non-injection alternatives, a segment projected to significantly contribute to the pharmaceutical market in the coming years.